Ionis Pharmaceuticals has earned a $5 million milestone payment from Janssen Biotech associated with the validation of an undisclosed target to treat patients with a gastrointestinal (GI) autoimmune disease. Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. “In just two short years, our collaboration with Janssen has proven to be very successful. Earlier this year, we earned $10 million when Janssen licensed IONIS-JBI1-...